Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019 · The Lancet · 2,108 citations
https://doi.org/10.1016/s0140-6736(19)32222-6